Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.71 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.64 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.64 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dihydromorphine SCHEMBL12402795 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 | |
| Dihydromorphine SCHEMBL2696539 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 | |
| Dihydromorphine SCHEMBL29394226 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 | |
| Dihydromorphine SCHEMBL19107002 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 | |
| Dihydromorphine SCHEMBL13348852 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 | |
| Dihydromorphine SCHEMBL26346 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 | |
| Dihydromorphine SCHEMBL19645038 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 | |
| Dihydromorphine SCHEMBL19615483 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 | |
| Dihydromorphine SCHEMBL17025853 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 | |
| Dihydromorphine SCHEMBL15449768 | 1.00 | OPRD1 (0.71) | OPRD1OPRK1OPRM1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524904-B2 | Process for the preparation of 6-alpha-hydroxy-N-alkylated opiates | MALLINCKRODT LLC (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524904-B2 | Process for the preparation of 6-alpha-hydroxy-N-alkylated opiates | MALLINCKRODT LLC (US) | 2013-09-03 | — | — | US | disclosed |
| US-20100081818-A1 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates | MALLINCKRODT INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081818-A1 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates | MALLINCKRODT INC. (US) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081818-A1 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates | OPRM1, OPRD1, OPRK1 | OPRD1 2/4885OPRK1 3/4885OPRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.